Methotrexate for Central Serous Chorioretinopathy Treatment Trial (MTX4CSC)

Edward Averbukh

Status and phase: Unknown; Phase 2

Conditions: Central Serous Chorioretinopathy

Treatments: Drug: Delayed treatment; Drug: Methotrexate

Study type: Interventional

Funder types: Other

Identifiers

NCT01633983

khateb-HMO-CTIL

Details and patient eligibility

About

Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may be beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision.

Full description

Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the center of the macula in adults of working age. Though previously the condition was considered stress-related, multiple recent reports have indicated correlation of appearance of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids is upregulated in many inflammatory conditions, control of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few short retrospective series of beneficial effect of MTX on CSC were reported recently. The investigators are going to try an escalating doses of MTX to treat CSC under full medical supervision in a prospective manner.

Enrollment: 20 estimated patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Central Serous Chorioretinopathy

Exclusion criteria

• Pregnancy
• Liver disease
• Kidney disease
• Steroid use

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

Methotrexate

Experimental group

Description:

Chronic CSC will be given an immediate MTX treatment

Treatment:

Drug: Methotrexate

Delayed treatment

Experimental group

Description:

Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered

Treatment:

Drug: Delayed treatment